HC Wainwright Issues Optimistic Forecast for ATRA Earnings

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Investment analysts at HC Wainwright increased their Q3 2025 earnings estimates for shares of Atara Biotherapeutics in a note issued to investors on Tuesday, January 28th. HC Wainwright analyst R. Burns now expects that the biotechnology company will post earnings per share of $3.57 for the quarter, up from their previous forecast of $3.35. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Atara Biotherapeutics’ current full-year earnings is ($9.86) per share.

Several other research firms also recently commented on ATRA. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Canaccord Genuity Group decreased their price target on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, January 17th. RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. Finally, Rodman & Renshaw began coverage on Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.75.

Atara Biotherapeutics Trading Up 13.4 %

NASDAQ ATRA opened at $8.36 on Wednesday. Atara Biotherapeutics has a 12 month low of $5.40 and a 12 month high of $39.50. The stock has a market cap of $48.15 million, a PE ratio of -0.32 and a beta of 0.51. The stock’s 50 day moving average is $11.83 and its 200 day moving average is $9.94.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the previous year, the firm earned ($16.50) earnings per share.

Institutional Trading of Atara Biotherapeutics

Large investors have recently made changes to their positions in the business. Vestal Point Capital LP lifted its holdings in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after acquiring an additional 12,677 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Atara Biotherapeutics in the 2nd quarter valued at approximately $79,000. State Street Corp lifted its stake in shares of Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the last quarter. FMR LLC boosted its holdings in shares of Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 7,381 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Atara Biotherapeutics during the 2nd quarter valued at approximately $53,000. 70.90% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.